-
Mashup Score: 4
Shaida Ouladan: Chimeric Antigen Receptor-T Cells in Colorectal Cancer / American Society of Clinical Oncology, cancer, CAR T-cell therapy, clinical trials,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2THE ONCOALERT NETWORK - 2 year(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Shilpa Gupta on Urothelial Carcinoma Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab - The ASCO Post - 2 year(s) ago
2023 ASCO Annual Meeting Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Ultrasound of malignant uterine mass: degenerative versus necrotic cystic manifestations and lack of structure - 2 year(s) ago
Uterine sarcomas are rare and difficult to diagnose on ultrasound, especially leiomyosarcomas diiferentiati0n from fibroids and degenerative changes. Ultrasound features suspicious of malignant fibroids are non-specific, inconsistent, and include irregular mass, irregular cystic areas, and/or rich
Categories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1THE ONCOALERT NETWORK - 2 year(s) ago
THE ONCOALERT NETWORK
Source: THE ONCOALERT NETWORKCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 7Thoracic Cancer - 2 year(s) ago
Thoracic Cancer
Source: ASCOCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 3THE ONCOALERT NETWORK - 2 year(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations - 2 year(s) ago
Abstract. Oncogenic activation of fibroblast growth factor receptor 2 (FGFR2) drives multiple cancers and represents a broad therapeutic opportunity, yet selective targeting of FGFR2 has not been achieved. While the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2 fusion-positive intrahepatic cholangiocarcinoma, their benefit is limited by incomplete…
Categories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 3THE ONCOALERT NETWORK - 2 year(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Drug Shortages - 2 year(s) ago
Find ASCO resources related to drug shortages
Source: ASCOCategories: Latest Headlines, Oncologists2Tweet
RT @OncoDailyIO: Chimeric Antigen Receptor-T Cells in Colorectal Cancer - @ShaidaOuladan @JCO_ASCO https://t.co/oqUTmtezFa #Cancer #Crcs…